CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
TW254946B
(zh)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
NZ272608A
(en)
|
1994-07-22 |
2000-05-26 |
Lilly Co Eli |
Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US5705151A
(en)
|
1995-05-18 |
1998-01-06 |
National Jewish Center For Immunology & Respiratory Medicine |
Gene therapy for T cell regulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
JP3437685B2
(ja)
|
1995-09-12 |
2003-08-18 |
株式会社東芝 |
交直変換装置の制御保護システム
|
AU7340096A
(en)
|
1995-11-07 |
1997-05-29 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
TR199902866T2
(xx)
*
|
1997-05-23 |
2000-02-21 |
Sikiric Predrag |
Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
|
US6426383B1
(en)
|
1997-05-28 |
2002-07-30 |
Nalco Chemical Company |
Preparation of water soluble polymer dispersions from vinylamide monomers
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
US6288082B1
(en)
*
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
JP4548642B2
(ja)
|
1998-09-29 |
2010-09-22 |
アメリカン・サイアナミド・カンパニー |
プロテインチロシンキナーゼインヒビターとしての置換3−シアノキノリン
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
TWI256395B
(en)
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
US20020048610A1
(en)
*
|
2000-01-07 |
2002-04-25 |
Cima Michael J. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
EP1257541B1
(en)
|
2000-01-11 |
2008-09-03 |
Molecular Insight Pharmaceuticals, Inc. |
Polypharmacophoric agents
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
TWI310684B
(en)
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
GB0008368D0
(en)
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
DK1318837T3
(da)
|
2000-08-11 |
2005-01-10 |
Wyeth Corp |
Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
BR0208627A
(pt)
|
2001-04-06 |
2004-03-09 |
Wyeth Corp |
Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
PL367267A1
(en)
|
2001-06-01 |
2005-02-21 |
Wyeth |
Antineoplastic combinations
|
US20020198137A1
(en)
|
2001-06-01 |
2002-12-26 |
Wyeth |
Antineoplastic combinations
|
CA2753372C
(en)
|
2001-06-14 |
2018-08-07 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
BR0214485A
(pt)
|
2001-11-27 |
2004-09-14 |
Wyeth Corp |
3-cianoquinolinas como inibidores de egf-r e her2 quinases
|
CA2472341C
(en)
|
2002-02-01 |
2011-06-21 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing compounds & uses thereof
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
WO2003106622A2
(en)
|
2002-05-30 |
2003-12-24 |
The Children's Hospital Of Philadelphia |
Methods for treatment of acute lymphocytic leukemia
|
BR0311814A
(pt)
|
2002-06-05 |
2005-03-15 |
Cedars Sinai Medical Center |
Método de tratar câncer empregando inibidores de cinase
|
US20060094674A1
(en)
|
2002-07-05 |
2006-05-04 |
Neel Benjamin G |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
CN1437942A
(zh)
|
2003-02-08 |
2003-08-27 |
杭州华卫制药技术开发有限公司 |
注射用长春瑞滨粉针剂及制备方法
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
KR20060006058A
(ko)
|
2003-04-22 |
2006-01-18 |
와이어쓰 |
항신생물성 배합물
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
DK1663978T3
(da)
|
2003-07-23 |
2008-04-07 |
Bayer Pharmaceuticals Corp |
Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
WO2005018677A2
(en)
|
2003-08-01 |
2005-03-03 |
Wyeth Holdings Corporation |
Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
|
MXPA06001590A
(es)
|
2003-08-19 |
2006-05-19 |
Wyeth Corp |
Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
EP1670473A1
(en)
|
2003-09-15 |
2006-06-21 |
Wyeth a Corporation of the State of Delaware |
Substituted quinolines as protein tyrosine kinase enzyme inhibitors
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
WO2005049021A1
(en)
|
2003-11-03 |
2005-06-02 |
Oy Helsinki Transplantation R & D Ltd |
Materials and methods for inhibiting neointimal hyperplasia
|
CA2566823A1
(en)
|
2003-11-05 |
2005-05-19 |
Board Of Regents, The University Of Texas System |
Diagnostic and therapeutic methods and compositions involving pten and breast cancer
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
US7235564B2
(en)
|
2003-12-04 |
2007-06-26 |
Amr Technology, Inc. |
Vinorelbine derivatives
|
US9016221B2
(en)
|
2004-02-17 |
2015-04-28 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
EP1733056B1
(en)
|
2004-03-31 |
2013-05-22 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
EP1748998B1
(en)
*
|
2004-05-28 |
2010-01-27 |
Hetero Drugs Limited |
A novel stereoselective synthesis of benzimidazole sulfoxides
|
WO2005118876A2
(en)
|
2004-06-04 |
2005-12-15 |
Genentech, Inc. |
Egfr mutations
|
JP2008507264A
(ja)
|
2004-07-23 |
2008-03-13 |
アストラゼネカ アクチボラグ |
Erbb受容体への薬剤に対する腫瘍の応答性を予測する方法
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
MX2007004489A
(es)
|
2004-10-13 |
2007-09-21 |
Wyeth Corp |
Analogos de 17-hidroxiwortamina como inhibidores pi3k.
|
US20080254497A1
(en)
|
2004-10-15 |
2008-10-16 |
Monogram Biosciences, Inc. |
Response Predictors for Erbb Pathway-Specific Drugs
|
US20060084666A1
(en)
|
2004-10-18 |
2006-04-20 |
Harari Paul M |
Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
|
WO2006085168A2
(en)
|
2005-01-07 |
2006-08-17 |
Ranbaxy Laboratories Limited |
Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
CN101155579B
(zh)
|
2005-02-03 |
2012-10-31 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
MX2007009963A
(es)
|
2005-02-24 |
2007-09-26 |
Amgen Inc |
Mutaciones del receptor del factor de crecimiento epidermico.
|
EP1859793B1
(en)
|
2005-02-28 |
2011-04-20 |
Eisai R&D Management Co., Ltd. |
Novel combinational use of a sulfonamide compound in the treatment of cancer
|
JP5159303B2
(ja)
|
2005-03-03 |
2013-03-06 |
武田薬品工業株式会社 |
放出制御組成物
|
ES2441019T3
(es)
|
2005-03-09 |
2014-01-31 |
Abbott Laboratories |
Métodos de diagnóstico para identificar pacientes candidatos para el tratamiento con trastuzumab
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
US20060235006A1
(en)
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
BRPI0610574A2
(pt)
|
2005-04-14 |
2010-07-06 |
Wyeth Corp |
uso de um inibidor de quinase para receptor do fator de crescimento epidérmico (egfr) em pacientes resistentes a gefitinib
|
US20110045459A1
(en)
|
2005-04-21 |
2011-02-24 |
Mischel Paul S |
Molecular determinants of EGFR kinase inhibitor response in glioblastoma
|
PT1896034E
(pt)
|
2005-04-28 |
2010-05-06 |
Wyeth Llc |
Composições de tanaproget micronizado e métodos para a sua preparação
|
MX2007014087A
(es)
|
2005-05-12 |
2008-02-07 |
Pfizer |
Combinaciones y procedimientos para usar un compuesto de indolinona.
|
BRPI0610144A2
(pt)
|
2005-05-25 |
2010-06-01 |
Wyeth Corp |
método de preparar um 3-cianoquinolina substituìda; composto representado pela fórmula i; e composto, representado pela fórmula ii
|
EP1883631A1
(en)
*
|
2005-05-25 |
2008-02-06 |
Wyeth |
Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
BRPI0613484A2
(pt)
|
2005-07-15 |
2016-11-16 |
Wyeth Corp |
composição de liberação mantida de dvs (succinato de o-desmetilvenlafaxina) superbiodisponível, uso de uma composição de dvs superbiodisponível, processos para o tratamento de depressão em um sujeito e para a redução dos efeitos colaterais da desvenlafaxina em um sujeito, embalagem farmacêutica
|
US20100105031A1
(en)
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
EP1931798A1
(en)
|
2005-10-05 |
2008-06-18 |
AstraZeneca UK Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
US20110052570A1
(en)
|
2005-10-26 |
2011-03-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
AR058505A1
(es)
|
2005-11-04 |
2008-02-06 |
Wyeth Corp |
Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
|
EP1948180B1
(en)
|
2005-11-11 |
2013-03-13 |
Boehringer Ingelheim International GmbH |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
EP1951274B1
(en)
|
2005-11-24 |
2009-12-02 |
AiCuris GmbH & Co. KG |
Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
|
JP2007145745A
(ja)
|
2005-11-25 |
2007-06-14 |
Osaka Univ |
変異型EGFR下流シグナルを抑制するSrcファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
|
EP1965770A2
(en)
|
2005-12-22 |
2008-09-10 |
Wyeth a Corporation of the State of Delaware |
Oral formulations comprising tigecycline
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
CA2644841C
(en)
|
2006-04-07 |
2013-07-16 |
Novartis Ag |
Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
IL282783B2
(en)
|
2006-05-18 |
2023-09-01 |
Caris Mpi Inc |
A system and method for determining a personalized medical intervention for a disease stage
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
ES2427924T3
(es)
|
2006-06-30 |
2013-11-04 |
Merck Sharp & Dohme Corp. |
Biomarcador IGFBP2
|
CA2663599A1
(en)
|
2006-09-18 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring egfr mutations
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
EP2073823A1
(en)
|
2006-10-13 |
2009-07-01 |
Medigene AG |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
WO2008076257A2
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Treating cancer with anti-igflr antibody 19d12 = sch 717454
|
WO2008076278A2
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Methods of cancer treatment with igf1r inhibitors
|
CN101605540A
(zh)
|
2006-12-14 |
2009-12-16 |
埃克塞利希斯股份有限公司 |
使用mek抑制剂的方法
|
WO2008076143A1
(en)
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
MX2009006700A
(es)
|
2006-12-21 |
2009-06-30 |
Vertex Pharma |
Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
|
PE20081632A1
(es)
|
2007-01-12 |
2008-12-10 |
Wyeth Corp |
Composiciones de tableta en tableta
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
US8697125B2
(en)
|
2007-02-01 |
2014-04-15 |
Takeda Pharmaceutical Company Limited |
Tablet preparation without causing a tableting trouble
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
EP1978106A1
(en)
|
2007-04-07 |
2008-10-08 |
Universitätsklinikum Hamburg-Eppendorf |
Detection of ESR1 amplification in endometrium cancer and ovary cancer
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
JP2010525326A
(ja)
|
2007-04-19 |
2010-07-22 |
ウェルスタット バイオロジックス コーポレイション |
分離されていない循環癌細胞由来のHer−2/neuタンパク質の上昇したレベルの検出および治療
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
US9732055B2
(en)
|
2007-09-10 |
2017-08-15 |
Boston Biomedical, Inc. |
Compositions and methods for cancer treatment
|
EP2205076A4
(en)
|
2007-09-24 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
POLYTHERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DOUBLE INHIBITORS OF EGFR ÝERBB1 AND HER-2 ÝERBB2
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
BRPI0819218A2
(pt)
|
2007-11-05 |
2015-05-05 |
Puretech Ventures |
Métodos, estojos e composições para administração de compostos farmacêuticos
|
CN101185633A
(zh)
|
2007-12-14 |
2008-05-28 |
山东蓝金生物工程有限公司 |
一种治疗实体肿瘤的尼拉替尼缓释植入剂
|
WO2009079587A2
(en)
|
2007-12-18 |
2009-06-25 |
Schering Corporation |
Biomarkers for sensitivity to anti-igf1r therapy
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
CN102016581B
(zh)
|
2008-02-25 |
2014-07-30 |
雀巢产品技术援助有限公司 |
用抗体阵列选择乳腺癌治疗药物
|
WO2009111073A2
(en)
|
2008-03-06 |
2009-09-11 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
WO2009142810A2
(en)
|
2008-03-25 |
2009-11-26 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
EP2977468B1
(en)
|
2008-03-27 |
2019-06-19 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in pulmonary arterial hypertension
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
US20110182888A1
(en)
|
2008-04-08 |
2011-07-28 |
Peter Ordentlich |
Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
|
BRPI0911422B8
(pt)
|
2008-04-18 |
2021-05-25 |
Reata Pharmaceuticals Inc |
compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
|
CA2721838C
(en)
|
2008-04-18 |
2017-05-23 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
|
WO2009146216A2
(en)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals. Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
CN102164941B
(zh)
|
2008-04-18 |
2015-05-27 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
|
MX2010011435A
(es)
|
2008-04-18 |
2011-01-25 |
Reata Pharmaceuticals Inc |
Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
|
JP2011519868A
(ja)
|
2008-05-05 |
2011-07-14 |
シェーリング コーポレイション |
癌を処置するための化学療法剤の連続投与
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
KR20130088908A
(ko)
|
2008-06-17 |
2013-08-08 |
와이어쓰 엘엘씨 |
Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물
|
JP5758801B2
(ja)
|
2008-07-22 |
2015-08-05 |
トラスティーズ・オブ・ダートマス・カレッジTrustees of Dartmouth College |
単環式シアノエノンおよびその使用方法説明
|
CN109464445A
(zh)
|
2008-08-04 |
2019-03-15 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
WO2010030835A2
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth Llc |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
EP3075864A1
(en)
|
2008-10-14 |
2016-10-05 |
Caris MPI, Inc. |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
JP2012508244A
(ja)
|
2008-11-07 |
2012-04-05 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
ErbB−3(HER3)選択的併用療法
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
RU2011136641A
(ru)
|
2009-02-04 |
2013-03-10 |
Байпар Сайенсиз, Инк. |
Лечение рака легких с применением соединения нитробензамида в комбинации с ингибитором фактора роста
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
EP3031807A1
(en)
|
2009-03-11 |
2016-06-15 |
Auckland UniServices Limited |
Prodrug forms of kinase inhibitors and their use in therapy
|
ES2941894T3
(es)
|
2009-04-06 |
2023-05-26 |
Wyeth Llc |
Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
WO2010129053A2
(en)
|
2009-05-05 |
2010-11-11 |
Dana Farber Cancer Institute |
Egfr inhibitors and methods of treating disorders
|
CN102470109A
(zh)
|
2009-07-02 |
2012-05-23 |
惠氏有限责任公司 |
3-氰基喹啉片剂制剂及其应用
|
KR20110007985A
(ko)
|
2009-07-17 |
2011-01-25 |
한올바이오파마주식회사 |
N,n―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
KR20110007984A
(ko)
|
2009-07-17 |
2011-01-25 |
한올바이오파마주식회사 |
N,n―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
KR101190953B1
(ko)
|
2009-08-25 |
2012-10-12 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
WO2011025271A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
WO2011025267A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
US20110055838A1
(en)
|
2009-08-28 |
2011-03-03 |
Moyes William A |
Optimized thread scheduling via hardware performance monitoring
|
AU2010302961A1
(en)
|
2009-10-01 |
2012-04-19 |
Csl Limited |
Method of treatment of philadelphia chromosome positive leukaemia
|
PT2498756T
(pt)
|
2009-11-09 |
2019-11-26 |
Wyeth Llc |
Formulações de comprimidos de maleato de neratinib
|
CA2780332C
(en)
|
2009-11-09 |
2018-01-30 |
Wyeth Llc |
Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
|
CN102812045B
(zh)
|
2009-11-13 |
2018-04-13 |
第一三共欧洲有限公司 |
用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法
|
JP2013512882A
(ja)
|
2009-12-07 |
2013-04-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
トリプルネガティブ乳癌の治療に使用するbibw2992
|
EP2510121A1
(en)
|
2009-12-11 |
2012-10-17 |
Wyeth LLC |
Phosphatidylinositol-3-kinase pathway biomarkers
|
CA2787048C
(en)
|
2010-01-13 |
2021-06-22 |
Wyeth Llc |
A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor
|